Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study

Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study

Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID...

Full description

Bibliographic Details
Main Authors: Yun Lu, Qing-qing Yang, Lin Zhuo, Kun Yang, Hao Kou, Su-yu Gao, Wen Hu, Qiao-li Jiang, Wen-jing Li, Dong-fang Wu, Feng Sun, Hong Cheng, Siyan Zhan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Microbiology
Subjects:
ambroxol
COVID-19
clinical outcomes
effectiveness
SARS-CoV-2
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2022.1013038/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2022.1013038/full

Similar Items